Niagen Bioscience (NAGE) Other Working Capital Changes (2020 - 2026)
Niagen Bioscience (NAGE) posted quarterly Other Working Capital Changes of -$102000.0 for Q1 2026, up 59.36% year-over-year from -$64005.0 in Q1 2025, and down 117.74% quarter-over-quarter from $575000.0 in Q3 2025.
Analysis
Niagen Bioscience (NAGE) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Other Working Capital Changes for 7 consecutive years, with -$102000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 59.36% year-over-year to -$102000.0; the TTM figure through Mar 2026 stood at $244000.0 (up 126.1% YoY), while the FY2025 annual figure was $95000.0, up 112.98% from the prior year.
- Other Working Capital Changes declined to -$102000.0 in Q1 2026 per NAGE's latest filing, from $575000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $2.8 million in Q3 2022 and bottomed at -$2.3 million in Q4 2022.
- Historically, Other Working Capital Changes has averaged -$8941.2 across 5 years, with a median of -$18000.0 in 2022.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes slumped 600.0% — and 2025, when it soared 355.56%.
- Niagen Bioscience's Other Working Capital Changes stood at -$152000.0 in 2022, then soared by 57.24% to -$65000.0 in 2023, then tumbled by 452.31% to -$359000.0 in 2024, then surged by 260.17% to $575000.0 in 2025, then sank by 117.74% to -$102000.0 in 2026.
- Business Quant data shows NAGE's Other Working Capital Changes at -$102000.0 in Q1 2026, $575000.0 in Q3 2025, and -$229000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -138,000.00 |
| Jun 30, 2026 | -138,000.00 |
| Mar 31, 2026 | -102,000.00 |
| Mar 31, 2026 | -102,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Sep 30, 2024 | -732,000.00 |
| Sep 30, 2024 | -732,000.00 |
| Dec 31, 2023 | -495,000.00 |
| Dec 31, 2023 | -495,000.00 |
| Dec 31, 2022 | -273,000.00 |
| Dec 31, 2022 | -273,000.00 |
| Sep 30, 2021 | -95,000.00 |
| Sep 30, 2021 | -95,000.00 |
| Dec 31, 2020 | 621,000.00 |
| Dec 31, 2020 | 621,000.00 |